A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

Completed · Phase 2

Conditions studied: Prostate Cancer, Cancer of Prostate, Prostatic Cancer, Cancer of the Prostate

In brief

A study for the treatment of hormone refractory prostate cancer (HRPC) in patients previously treated with chemotherapy.

Key facts

Study ID

NCT00257478

Run by

Astellas Pharma Inc

Expected to finish

2007-03-01

Last updated by the study team

2012-06-07

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed prostate cancer.
• Prior chemotherapy regimen for prostate cancer

You may not qualify if…

• History of other malignancy in the last 5 years
• Major surgery within the past 21 days

Where it is running

• Study site — Tuscon, Arizona, United States
• Study site — Los Angeles, California, United States
• Study site — Coeur d'Alene, Idaho, United States
• Study site — New York, New York, United States
• Study site — The Bronx, New York, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — San Antonio, Texas, United States
• Study site — Amsterdam, Netherlands
• Study site — Sutton, Surry, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.